Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France

Nadim Cassir, Florian Cardona, Hervé Tissot-Dupont, Christiane Bruel, Barbara Doudier, Salima Lahouel, Karim Bendamardji, Céline Boschi, Sarah Aherfi, Sophie Edouard, Jean-Christophe Lagier, Philippe Colson, Philippe Gautret, Pierre-Edouard Fournier, Philippe Parola, Philippe Brouqui, Bernard La-Scola, Matthieu Million

We enrolled 136 patients with laboratory-confirmed monkeypox during June 4-August 31, 2022, at the University Hospital Institute Méditerranée Infection in Marseille, France. The median patient age was 36 years (interquartile range 31-42 years). Of 136 patients, 125 (92%) were men who have sex with men, 15 (11%) reported previous smallpox vaccinations, and 21 (15.5%) were HIV-positive. The most frequent lesion locations were the genitals (68 patients, 53%), perianal region (65 patients, 49%), and oral/perioral area (22 patients, 17%). Lesion locations largely corresponded with the route of contamination. Most (68%) patients had isolated anal, genital, or oral lesions when they were first seen, including 56 (61%) who had ≥1 positive site without a visible lesion. Concurrent sexually transmitted infections were diagnosed in 19 (15%) patients, and 7 patients (5%) were asymptomatic. We recommend vaccination campaigns, intensified testing for sexually transmitted infections, and increased contact tracing to control the ongoing monkeypox outbreak.

Monkeypox virus (MPXV), a zoonotic orthopoxvirus related to smallpox virus, was first described in humans in 1970 in the Democratic Republic of the Congo (1). Sporadic outbreaks of infection have been reported in Africa, typically occurring because of close contact with wild rodents, which represent the primary reservoir (2). Those outbreaks and travel-associated cases outside of Africa have been characterized by limited secondary spread (3). A new outbreak began in May 2022, when autochthonous cases of MPXV infection were initially reported in England and, subsequently, throughout Europe. The World Health Organization declared monkeypox a public health emergency on July 23, 2022 (4,5). As of September 6, 2022, a total of 54,911 laboratoryconfirmed cases of monkeypox and 15 monkeypoxrelated deaths had been reported to the World Health Organization by 100 countries. Genomic analysis of viral strains causing the current outbreak revealed a distinct phylogenetic lineage of human MPXV. This lineage (B.1, belonging to clade IIb) is characterized by a heightened mutational signature compared with its ancestors and has been associated with milder disease than clade I (6).

Initial reports on the ongoing monkeypox outbreak suggest that cases have been atypical; patients have had rashes appearing on fewer regions of the body, frequent genital and perianal lesions, less frequent prodromal symptoms, and a generally benign course of disease (2,7–10). In contrast, in monkeypoxendemic countries in Africa, monkeypox predominantly affects young children and is characterized by rashes incorporating many simultaneous lesions in multiple regions of the body, including the face, that are associated with diffuse lymphadenopathy. The

Author affiliations: IHU-Méditerranée Infection, Marseille, France (N. Cassir, F. Cardona, H. Tissot-Dupont, B. Doudier, S. Lahouel, K. Bendamardji, C. Boschi, S. Aherfi, S. Edouard, J.-C. Lagier, P. Colson, P. Gautret, P.-E. Fournier, P. Parola, P. Brouqui, B. La-Scola, M. Million); Aix-Marseille Université, IRD, AP-HM, MEPHI, Marseille (N. Cassir, H. Tissot-Dupont, C. Boschi, S. Aherfi, S. Edouard, J.-C. Lagier, P. Colson, P. Gautret, P. Brouqui, B. La-Scola, M. Million); Assistance Publique Hôpitaux de Marseille, Marseille (F. Cardona, B. Doudier, S. Lahouel, K. Bendamardji); Regional Health Agency of Provence-Alpes-Côte d'Azur (ARS Paca), Marseille (C. Bruel); Aix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille (P.-E. Fournier, P. Parola)

DOI: https://doi.org/10.3201/eid2812.221440

RESEARCH

southern France*	
Variable	No. patients†
Age, y, median (IQR)	36 (30–42)
Sex	
F	3 (2.2)
Μ	133 (97.8)
Sexual orientation	
Men who have sex with men	125 (91.9)
Using PrEP	30 (24)
Heterosexual men	2 (1.5)
Heterosexual women	3 (2.2)
History of smallpox vaccination	
Childhood vaccine	7 (5.1)
Postexposure vaccine	6 (4.4)
Preexposure vaccine	2 (1.5)
HIV-positive	
Total	21 (15.4)
<500 CD4/mm ³	5 (23.8)
<200 CD4/mm ³	0
Possible exposure to monkeypox	
Sexual partner with monkeypox	21 (15.4)
New sexual partners‡	115 (84.6)
Attendance at a Pride event	7 (5.2)
Recent travel to an endemic country	0
Recent travel to an epidemic country	17 (12.5)
*Values are no. (%) patients except as indicated. PrEP	, preexposure
prophylaxis; CD4, CD4 T lymphocyte.	
† I otal number of patients in the study was 136.	04 -
ISingle or multiple new sexual partners in the previous	5 Z 1 Q.

Table 1. Demographic and epidemiologic characteristics of
patients with monkeypox in Marseille during the 2022 outbreak in
southern France*

rash is preceded by systemic prodromal symptoms (3). Complications include pneumonitis, encephalitis, keratitis, and secondary bacterial infections. The case fatality rate ranges from 1%–10% depending on immune status and clade (2). However, these data come from relatively old studies in low resource settings where access to healthcare is limited; minor cases are almost certainly underreported, and ascertainment of cause of death is incomplete.

Detailed information regarding the changing epidemiology of monkeypox during the 2022 outbreak is needed. In this study, we aimed to comprehensively evaluate the epidemiologic, clinical, and virologic features of 136 patients who had a monkeypox diagnosis at the University Hospital Institute Méditerranée Infection in Marseille, France.

Materials and Methods

Study Design and Participants

In this retrospective, observational cohort study, we enrolled consecutive patients who had a monkeypox diagnosis during June 4–August 31, 2022, at the University Hospital Institute Méditerranée Infection in Marseille, France. We defined a confirmed monkeypox case as a positive real-time PCR result from skin, genital, rectal, or pharyngeal swab samples. We performed contact tracing and follow-up in collaboration with the regional health agency after mandatory declarations were made to the health agency. Asymptomatic patients were tested when they reported recent high-risk exposure. We only included adult patients in the analysis who had laboratory-confirmed monkeypox. Treatment was prescribed according to national standard of care procedures. Imvanex (Bavarian Nordic, https://www.bavarian-nordic.com) was the vaccine used in France for the preexposure and postexposure vaccination against MPXV.

Ethics Approval

The study was approved by the ethics committee at the University Hospital Institute Méditerranée Infection (no. 039-2022) and declared to the Règlement Général de la Protection des Données registry (no. 22-340). We extracted medical data from the hospital's electronic medical records system. We obtained oral informed consent from all patients in accordance with the Declaration of Helsinki (revised in 2013) and written informed consent for publication of clinical images when needed.

Laboratory Procedures

Laboratory confirmation of orthopoxvirus, including monkeypox virus, was performed at the University Hospital Institute Méditerranée Infection in Marseille, France. We tested skin, genital, rectal, and pharyngeal swabs for MPXV by using in-house real-time PCR (11). Genital or rectal swab refers to sampling of skin/mucosal lesions in the genital or rectal areas. No anoscopies were performed in this cohort. For 127 patients who were enrolled after being informed, we tested clinical samples for other sexually transmitted infections (STI) by using quantitative PCR to detect specific pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum, herpesvirus, and Trichomonas vaginalis as previously described (12,13). Using serologic methods, we also tested for hepatitis B virus, hepatitis C virus, HIV, and syphilis in 9 of those 127 patients. All patients were examined in an isolation room where samples were collected for analysis. Sample collection to diagnose monkeypox and other STIs evolved during the time of the study, focusing first on the rash lesion and then associated systematically with pharyngeal, rectal, and genital swabbing together with blood samples for serologies contingent upon the patient's agreement. We handled all samples in a Biosafety Level 3 laboratory.

Data

We established case definitions before beginning data collection. For all patients attending our institute

for suspected monkeypox infection, we used a standardized medical questionnaire (in English or French) (Appendix Figures 1, 2, https://wwwnc. cdc.gov/EID/article/28/12/22-1440-App1.pdf) to obtain demographic information; patient's reported smallpox vaccination; HIV status; epidemiologic data, including exposure to someone with monkeypox, travel, attendance at large gatherings, and risk factors for sexually transmitted infections; sexual practices; symptoms; virologic results at multiple body sites, including analysis of PCR cycle threshold (Ct) values; and co-infection with other sexually transmitted pathogens.

We classified sexual orientation as heterosexual or men who have sex with men (MSM) according to the patient's declaration. We defined acute proctitis as perianal lesions with rectal pain because there were no cases of rectal pain without lesions. We defined tonsillitis as a sore throat and exanthem as a widespread maculopapular rash.

Statistical Analysis

We reported continuous variables as medians with interquartile ranges (IQRs), where appropriate, and categorical variables as absolute values and percentages. We compared continuous variables by using Mann-Whitney or Kruskal-Wallis nonparametric tests. All tests were 2-sided with a significance threshold of p<0.05. We performed all analyses by using the statistical package R version 4.0.3 (The R Project for Statistical Computing, https://www.r-project.org). We generated graphs using Prism for Mac version 9.0 (GraphPad, https://www.graphpad.com).

Results

We enrolled a total of 136 patients who had a laboratory-confirmed monkeypox diagnosis; 133 were men, and 3 were women. We collected demographic (Table 1), clinical (Table 2), and microbiological (Table 3) information for the patients. We determined 125 (92%) patients were MSM and 5 (4%) patients were heterosexual. Information on sexual orientation was not available for the remaining 6 patients. The median age was 36.0 (IQR 30.0-42.0) years. Of the 136 enrolled patients, 15 (11%) reported previous smallpox vaccination, and 21 (16%) were HIV-positive, of whom 5 (24%) had a CD4 cell count of <500 cells/ mm³. Among 3 heterosexual women, only 1 declared that her regular sexual partner had a monkeypox diagnosis, and the other 2 reported a new sexual partner within the previous 3 weeks. Travel to MPXV-endemic regions was not reported by any patient, whereas 17 (12.5%) reported recent travel to a country that is

part of the current outbreak, which includes Spain (n = 11 patients), United States (n = 2 patients), Germany (n = 1 patient), Belgium (n = 1 patient), Canada (n = 1 patient), and Italy (n = 1 patient). Seven (5.2%) patients had attended a Pride event in the previous 21 days in Spain (n = 2) and France (n = 5). The most frequent lesions were located in the genital (68 [53%] patients), perianal (65 [49%] patients), and oral/perioral (22 [17%] patients) areas (Figure 1). The number of skin lesions was ≤ 10 in 98 (73%) patients. An asynchronous rash was observed in 41 (30%) of 129 symptomatic patients. Localized lymphadenopathy in lesion areas was observed in 47 (36.4%) patients. Systemic manifestations before or when the patient was first seen included fever (72 [56%] patients), influenza-like illness (44 [35%] patients), and sore throat (11 [8.5%] patients), which preceded the rash in 90 (70%) patients.

Table 2. Clinical characteristics of symptomatic patients with
monkeypox in Marseille during the 2022 outbreak in southern
France*

Variable	No. (%) patients
Systemic features	
>1 systemic feature	98 (73)
Systemic symptoms before rash onset	90 (69.8)
Fever	72 (55.8)
Influenza-like illness	44 (35.1)
Sore throat	11 (8.5)
Clinical features of rash	
Approximate number of lesions	
>50	0
11–50	17 (13.2)
1–10	98 (73)
Type of lesion	
Papular	26 (21)
Vesicular	60 (49)
Pustular	25 (20)́
Scabbed	10 (7.8)
Asynchronous rash	41 (<u>3</u> 0.1)
Lesion location	· · · · ·
Genital	68 (52.7)
Perianal	63 (48.8)
Oral ulcer	3 (2.3)
Perioral	22 (17.1)
Hands and feet	13 (10.1)
Trunk	28 (21.7)
Lymphadenopathy	
Any lymphadenopathy	51 (39.5)
Regional at site of lesion	47 (36.4)
Cervical	26 (20.2)
Inguinal	28 (21.7)
Generalized	4 (3.1)
Complications	
Any complication	34 (26.4)
Complication by type	
Proctitis	30 (23.3)
Tonsillitis	5 (3.9)
Penile edema	5 (3.9)
Bacterial skin abscess	4 (3.1%)
Exanthem	3 (2.3%)

*Total number of patients evaluated was 129.

RESEARCH

Tance		
	Positive	
Variable	samples/total (%)	Mean Ct (SD)
PCR results		
Skin swabs	69/84 (82)	28.3 (4.7)
Genital swabs	67/69 (97)	26.2 (4.0)
Throat swabs	50/116 (43)	32.2 (3.4)
Rectal swabs	68/105 (65)	26.1 (5.2)
Concurrent STIs		
HIV	2/9 (22.2)	NA
Chlamydia trachomatis	4/127 (3.1)	NA
Neisseria gonorrhoeae	13/127 (10.2)	NA
Mycoplasma genitalium	1/127 (0.8)	NA
Syphilis	4/127 (3.1)	NA
Trichomonas vaginalis	1/127 (0.8)	NA
Other STIs	19/127 (15)	NA
*Ct, cycle threshold; STI, sexuall	y transmitted infection; N	VA, not applicable.

 Table 3. PCR and microbiological results for patients with monkeypox in Marseille during the 2022 outbreak in southern France*

A concomitant diagnosis of another STI occurred for 19 (15%) patients, including 2 patients who had a new diagnosis of HIV-1 infection. Of 63 patients with perianal lesions, 55 (87.3%) reported practicing receptive anal sex, and 12 (19%) had concomitant *N. gonorrhoeae* (n = 9), *C. trachomatis* (n = 2), or *M. genitalium* (n = 1) infections diagnosed from a rectal swab sample. Of 23 patients with oral ulcers or peri-oral lesions, 6 (26%) had concomitant *N. gonorrhoeae* (n = 4), *C. tra*- *chomatis* (n = 1), or *T. vaginalis* (n = 1) infections, and 20 (87%) reported practicing oral-receptive sex. Concomitant syphilis was diagnosed in 1 patient from a genital swab sample, and 3 patients had serologic results indicating active syphilis infections.

We observed complications in 37 (27%) patients, which included proctitis (n = 30), tonsillitis (n = 5), penile edema (n = 5), skin abscesses (n = 5), and exanthem (n = 3). Hospital admission was required for 6 (4.5%) patients, some of whom had multiple issues; 5 required perianal pain relief, 3 required management of bacterial abscesses, 1 had dysphagia because of oral lesions, and 1 was admitted for social reasons. All 6 patients had favorable outcomes. None of the patients received antiviral treatment. Opioid prescription for perianal pain relief was required for 3 hospitalized patients and 2 outpatients.

We determined the PCR Ct values were lower for skin, genital, and rectal swabs (combined mean) than for pharyngeal specimens (mean Ct \pm SD 27.4 \pm 4.9 vs. 32.2 \pm 3.4; p<0.0001) (Figure 2). Of 129 symptomatic patients, 15 (12%) had samples taken from 4 sites (pharynx, rectum, skin lesion, genital lesion), 73 (57%) had samples taken from 3 sites, 43 (33%) had samples taken from 2 sites, and 5 (4%) had samples



Figure 1. Sites of monkeypox lesions in observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France, 2022. A) Primary inoculation site showing an irregular pustule with necrotic crust of the right nipple. B) Pustular lesions with a crusted center on the mucosa of the upper lip, close to the left oral commissure and left nasal orifice. C) Pustules circumferentially distributed on the anal margin and perianal skin of varying sizes and stages of evolution; some with central necrotic crusts. D) Perineally extended purpuric lesions. E) Scrotal lesions of varying sizes and stages of evolution with edema surrounding the larger ulcero-hemorrhagic ulcers. F) Scattered papules, pustules, and umbilicated pustules surrounded by an erythematous halo on the back. G) Reddened and swollen right palatine tonsil with a fibrin-covered ulcer. H) Pustular lesion of the nose with a necrotic central crust, whitish deposit, and erythematous halo.

taken from only 1 site (4 skin swabs, 1 genital swab). We observed 92 (68%) patients with isolated anal, genital, skin, or oral lesions when they were first seen, including 56 (61%) patients who had \geq 1 other PCR-positive site without visible lesions. Some PCR-positive samples did not come from visible lesions at the time of testing (40/50 oropharyngeal, 4/67 genital, and 5/68 rectal samples). PCR Ct values from the lesions were not significantly different from those for sites that had no visible lesions (data not shown). The combination of genital and rectal swab testing led to the diagnosis of 111 (86%) MPX cases.

We determined that 7 (5%) patients were asymptomatic; 1 had an MPXV-positive pharyngeal sample and 6 had MPXV-positive rectal samples. We showed that the PCR Ct values obtained from rectal swabs were not significantly different between asymptomatic patients (n = 6) and symptomatic patients (n = 62) (Appendix Figure 3). None of the asymptomatic patients had been previously vaccinated against smallpox virus. We did not find differences in clinical features and MPXV loads between clinical samples from patients who reported receiving smallpox vaccination and those who did not receive vaccination (data not shown) or between patients who reported being HIVpositive and those who did not (Appendix Figure 4).

Discussion

We report epidemiologic, clinical, and virologic data from 136 patients who had confirmed monkeypox at the outpatient unit of the University Hospital Institute Méditerranée Infection in Marseille, France, during June 4-August 31, 2022. We observed systemic manifestations in approximately two thirds of these patients. Lymphadenopathy often occurred in lesion areas, which differs from that reported for endemic monkeypox in countries of Africa. We observed that the evolution of rashes in our study was also atypical because rashes did not always occur with monomorphic and synchronous vesicular umbilicated lesions (3). Similar to recent studies, the cases in our study occurred almost exclusively within the MSM community (2,7-10). However, the percentage of MSM in this study (92%) was lower compared with a previous multicountry report (98%) (2). Of note, both male patients in our study who identified as heterosexual had perianal lesions, which raises the question of reporting bias. We also found that most patients had a low number of lesions (<10) located in the genital, anal, and oral regions. Most patients had previous sexual exposure to a person known to have monkeypox or had high risk for sexually transmitted diseases, such as having single or multiple new sexual partners with-



Figure 2. Comparison of monkeypox virus loads between different clinical sampling sites in an observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France, 2022. Each colored circle indicates a tested sample; thick horizontal lines indicate mean values; error bars indicate SD. We tested clinical samples for monkeypox virus by using quantitative PCR. We collected samples from skin (n = 69), genital (n = 67), rectal (n = 68), and pharyngeal (n = 50) swabs and calculated the mean Ct for each sample type. Viral loads were significantly lower in skin, genital, and rectal samples compared with pharyngeal samples. Ct, cycle threshold.

in 21 days before their monkeypox diagnosis or attendance at a Pride event. Similar to results from 3 other large cohorts of patients with monkeypox (2,8,9), we found a high rate (15%) of concurrent STI diagnoses, including 2 patients with a new diagnosis of HIV-1 infection. These findings suggest that the sexual route was the main transmission method for amplification of the monkeypox outbreak. For example, 3 large MSM gatherings have been implicated as monkeypox amplifying and superspreading events in Antwerp, Belgium, and in Madrid and the Canary Islands, Spain (14). Although we did not collect this specific information, some patients in our study likely participated in these events. Furthermore, we found that MPXV PCR Ct values in skin, genital, and rectal swab samples were substantially lower than in pharyngeal swab samples. In contrast to a previous report (15), we found that MPXV PCR Ct values in genital and rectal swab samples were not significantly lower than those in skin swab samples. These differences might

RESEARCH

be explained in part by sampling bias; a single site swab might be insufficient for microbiological confirmation of monkeypox. Among clinical samples and independently of the lesion site, we found that genital swab specimens had the highest MPXV positivity rate (97%), followed by skin swab specimens (82%). Rectal swab specimens had a positivity rate of 65% and also contributed to a monkeypox diagnosis. In contrast, the MPXV positivity rate of pharyngeal swab samples was relatively low (43%). Genital and rectal swab specimens together had a remarkably high sensitivity (86%) in this patient cohort, which is noteworthy because these specimens are routinely collected in STI clinics. We also found that some positive samples did not come from areas with visible lesions at the time of testing. Testing specimens from multiple sites on persons with exposure history could, therefore, be relevant depending on the symptoms and potential risks the person had during close contact.

We observed that 15 patients had acquired monkeypox despite having been vaccinated against smallpox during childhood or having received a preexposure or postexposure vaccine. The median period between postexposure vaccination (first dose), and the onset of symptoms was 15 (IQR 8.6-22.4) days. Symptoms occurred at 33 and 35 days in 2 patients after first dose preexposure vaccination. These results warrant further investigation to determine the extent of protection provided by vaccination and highlight the insufficient protection provided by the first dose of vaccine. In addition, 15% of patients were HIVpositive, including 5 patients with CD4 cell counts of <500 cells/mm³. Clinical features and MPXV loads did not differ between persons who were HIV-positive and HIV-negative. None of the patients in our study had a CD4 cell count of <200 cells/mm³; therefore, we cannot extrapolate our results to immunocompromised patients. Although >25% of patients had complications that required supportive care and antimicrobial drugs for bacterial skin abscesses, we observed a benign course of disease that did not require antiviral therapy. Of note, hospitalized patients did not have conditions that were considered risk factors for a severe form of monkeypox, such as being immunocompromised, a child, or a pregnant or breastfeeding woman. However, to our knowledge, an evaluation of risk factors for severe outcomes during the current outbreak has not been performed. In a recent report on a cohort of 264 monkeypox cases (7), 6% of patients were hospitalized exclusively for the management of severe local complications at the site of the rash and for pain relief. All patients were men who were not immunosuppressed. Compassionate use of tecovirimat for the treatment of monkeypox infection has been proposed in some centers (16) but requires further evaluation and rational use considering the generally benign course of disease in the current outbreak.

In our study, 7 patients with laboratory-confirmed monkeypox were asymptomatic. In contrast, most large cohort studies during the outbreak have included only symptomatic patients who were positive for MPXV (2,7-9). We tested asymptomatic MSM attending our institute only when they reported recent high-risk exposure, and we likely underestimated the incidence of asymptomatic patients who had laboratory-confirmed monkeypox because this was not part of a systematic screening process. Positive MPXV quantitative PCR results have been identified from anal samples in 13/323 (4%) asymptomatic MSM by assessing the presence of MPXV in anorectal samples from asymptomatic MSM who were routinely tested for STIs (17). Moreover, MPXV was identified by PCR in anorectal samples from 3 asymptomatic men in another study; MPXV was cultured from 2 of these samples, indicating viral shedding that could lead to transmission (18). These findings suggest that testing and quarantine for only symptomatic persons might be insufficient to contain the current outbreak.

In conclusion, the ongoing human monkeypox outbreak features unusual characteristics, such as the predominant involvement of MSM who have isolated anal, genital, or oral lesions. The high proportion of concomitant STIs showed transmissibility of monkeypox occurred through local inoculations during sexual activity. Testing specimens from multiple sites in persons with relevant exposure history could be relevant, regardless of the presence of visible lesions. Furthermore, asymptomatic carriage of MPXV suggests that some monkeypox cases might remain undiagnosed, and testing and quarantine of only symptomatic patients might be insufficient to contain transmission. Undiagnosed infections might play a role in overall disease transmission during the outbreak among MSM who have a dense sexual network that includes anonymous contacts, which hampers efficient contact tracing. Physicians should be aware that monkeypox symptoms might overlap with those of other STIs, more specifically in MSM with at-risk sexual activity. Prevention, including vaccination campaigns targeting at-risk groups, are ongoing in multiple countries and should be expanded. Intensified testing for all STIs at different sites (pharynx, rectum, genital, and skin) and in urine and increased contact tracing might also be helpful to control the outbreak.

Acknowledgments

We thank Louisa Ousseni for her technical assistance.

About the Author

Dr. Cassir is a physician specialist in infectious diseases and researcher in clinical microbiology at the IHU Méditerranée Infection in Marseille, France. His main interests focus on the epidemiology of infectious diseases, human microbiota, antibiotic stewardship, and infection control.

References

- Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46:593–7.
- Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.; SHARE-net Clinical Group. Monkeypox virus infection in humans across 16 countries – April-June 2022. N Engl J Med. 2022;387:679–91. https://doi.org/10.1056/NEJMoa2207323
- Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al.; CDC Monkeypox Outbreak Team. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19:872–9. https://doi.org/10.1016/ S1473-3099(19)30294-4
- World Health Organization. Multi-country outbreak of monkeypox, external situation report #5-7 September 2022 [cited 2022 Sep 28]. https://www.who.int/publications/ m/item/multi-country-outbreak-of-monkeypox-external-situation-report--5---7-september-2022
- Vaughan AM, Cenciarelli O, Colombe S, Alves de Sousa L, Fischer N, Gossner CM, et al. A large multi-country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022. Euro Surveill. 2022;27:2200620. https://doi.org/10.2807/1560-7917.ES. 2022.27.36.2200620
- Luna N, Ramírez AL, Muñoz M, Ballesteros N, Patiño LH, Castañeda SA, et al. Phylogenomic analysis of the monkeypox virus (MPXV) 2022 outbreak: emergence of a novel viral lineage? Travel Med Infect Dis. 2022;49:102402. https://doi.org/10.1016/j.tmaid.2022.102402
- Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, et al. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study. Clin Microbiol Infect. 2022 Aug 23 [Epub ahead of print]. https://doi.org/10.1016/j.cmi.2022.08.012
- Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400:661–9. https://doi.org/10.1016/ S0140-6736(22)01436-2
- 9. Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of

confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022;22:1321–8. https://doi.org/10.1016/S1473-3099(22)00411-X

- Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022;378:e072410. https://doi.org/10.1136/bmj-2022-072410
- Scaramozzino N, Ferrier-Rembert A, Favier AL, Rothlisberger C, Richard S, Crance JM, et al. Real-time PCR to identify variola virus or other human pathogenic orthopox viruses. Clin Chem. 2007;53:606–13. https://doi.org/10.1373/clinchem.2006.068635
- Edouard S, Tamalet C, Tissot-Dupont H, Colson P, Ménard A, Ravaux I, et al. Evaluation of self-collected rectal swabs for the detection of bacteria responsible for sexually transmitted infections in a cohort of HIV-1-infected patients. J Med Microbiol. 2017;66:693–7. https://doi.org/10.1099/ jmm.0.000481
- Schirm J, Bos PAJ, Roozeboom-Roelfsema IK, Luijt DS, Möller LV. *Trichomonas vaginalis* detection using real-time TaqMan PCR. J Microbiol Methods. 2007;68:243–7. https://doi.org/10.1016/j.mimet.2006.08.002
- European Centre for Disease Prevention and Control. Epidemiological update: monkeypox multi-country outbreak. 2022 May 31 [cited 2022 Sep 28]. https://www.ecdc.europa.eu/en/news-events/ epidemiological-update-monkeypox-multi-country-outbreak-0
- Veintimilla C, Catalán P, Alonso R, de Viedma DG, Pérez-Lago L, Palomo M, et al. The relevance of multiple clinical specimens in the diagnosis of monkeypox virus, Spain, June 2022. Euro Surveill. 2022;27:2200598. https://doi.org/10.2807/1560-7917.ES.2022.27.33.2200598
- Desai AN, Thompson GR 3rd, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA. 2022;328:1348–50. https://doi.org/10.1001/ jama.2022.15336
- 17. Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, et al. Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. Ann Intern Med. 2022 Aug 16 [Epub ahead of print]. https://doi.org/10.7326/M22-2183
- De Baetselier I, Van Dijck C, Kenyon C, Coppens J, Michiels J, de Block T, et al.; ITM Monkeypox study group. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med. 2022 Aug 12 [Epub ahead of print]. https://doi.org/10.1038/s41591-022-02004-w

Address for correspondence: Nadim Cassir, Microbes, Evolution, Phylogeny and Infection, Aix-Marseille Université Institut de Recherche Pour le Développement IRD, Assistance Publique, Hôpitaux de Marseille, Institut Hospitalo-Universitaire Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385 Marseille CEDEX 05, France; email: nadimshams.cassir@ap-hm.fr Article DOI: https://doi.org/10.3201/eid2812.221440

Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France

Appendix

RRANÉE	ASSISTANCI PÖ	E PUBLIQUE -	HÖPITAUX IES INFECTI	DE MARSEILL EUSES	E Hôpitau Universitain de Marsoil
N N	IONK	ΈΥΡΟ	x	Patie	ent identity
ione num je:	ber:				
tory of sm Pre-exposi	allpox vaccina ure 🗆 Post-ex	tion 🛛 Yes 🗆 M posure	ła	First dose da Second dose	date
HIV serapa □ < 50	ositivity IO CD4/mm3	□ < 200 C	D4/mm3	D PrEP	
MSM	Hete	rosexual			
(POSURE Rect New Sext Mult	ent travel (last r sexual partne ral partner VF tiple sexual pa	3 weeks) Dest in the previou X inthers in the pr	ination : 15 3 weeks revious 3 wee	Date :	//
INICAL PR	RESENTATIO	N	Asymp	tomatic	
te of onset Feve Influ Lym	t of systemic fi er Jenza-like illne phadenopathy	eatures:/ iss 🗆 Sore th	./Date of	onset of lesions	: un//
Exar	nthema		740		
	Papular E Asynchrono	i vesicular us rash	Pustula	r 🗆 Sca	DDed N-
	Pruritic Hands and 1	eet 🛛 Trunk	Num	when on residues:	- <10
	Genital Genital				□ 10 à 50 □ > 50
1	Rectal				
	Bacterial sk	in abscess	Penile oedem	a	
ит но	433 4 www.mediter F.I.N.E.S SPITALO- Profe	UNIVERSI sseur Didier	relie France m FAIRE MÉ RAOULT – D	DITERRAN	IÉE INFEC
TUT HO	433.4 www.mdfer F.I.N.E.S SPITALO- Profe ASSISTANCI PÕ	UNIVERSII mere-infection.cc 5.13078506-9 UNIVERSII SSEUR DIGIER FUBLIQUE – LE DE MALAD	raire Mé raire Mé raoult – D Hôpitaux ies infecti	DITERRAN Virecteur DE MARSEILL EUSES	IÉE INFEC Hôpitau Universitain de Marsoil
TUT HO	essa www.moditer FINES SPITALO- Profe ASSISTANCI PÕ	UNIVERSI S. 13078500-9 UNIVERSI SSEUR DIGIER E PUBLIQUE – LE DE MALAD	TAIRE MÉ MAOULT - D HÓPITAUX IES INFECTI	DITERRAN Irecteur DE MARSEILL EUSES OUTCOME	LÉE INFEC E Hôpitau Understated de Marseil
RRANÉE RRANÉE Brankes Gen Brankes Skin Reat Urin	ess of www.oredifer F.I.R.C.S SPITALO- Profe ASSISTANCI PÖ rRT-PCR MP rgraf swab tal swab tal swab tal swab	III 73 ACO III 73 ACO III 73 ACO III 74 ACO IIII 74 ACO III 74 ACO IIII 74 ACO III 74 AC	In In Internet	DITERRAN Irecteur Content EUSES OUTCOME Ambulato Hospitala Treatment	ry ation
Imples for Branker Gen Skin Reet Urin	43.6 43.0 WWW.DHOHM FLINCS SPITALO- Prote ASSISTANCI PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PÕ PROTE PO PROTE PO PROTE PO PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROTE PROT	III 73 ACO III 73 ACO III 74 ACO S. 1307656-9 UNIVERSIT SSEUT DIGIET E PUBLIQUE – LE DE MALAD	In In RAOULT - D HÖPITAUX IES INFECTI	DITERRAN Irreteur DE MARSEILL EUSES OUTCOME Ambulato Hospitaliz Treatment:	LÉE INFEC
mples for Phate Skin Skin Reet	43.4 43.4 WWW.DHORMER FLINCS SPITALO- Prote ASSISTANCI PO rRT-PCR MP PMgral swab tal swab tal swab tal swab tal swab	UN 78 701 UN 78 701 S. 1327650-9 UN IVERSI Sseur Didler FUBLIQUE - LE DE MALAD XV DEMANDE D'E MONICEPED	TAIRE MÉ TAIRE MÉ	DITERRAN Irecteur DE MARSEILL EUSES OUTCOME Horpitala Treatment DLOGIQUES	ry ation IST
RRANÉE mples for Phat Gen Rect Urin	43.6 A	UNIVERSII Second Control of Cont	TAIRE MÉ TAIRE MÉ TAIRE MÉ TAIRE MÉ TAIRE ME TAIRE ME TAIRE ME TAIRE ME TAIRE ME TAIRE ME TAIRE ME TAIRE ME TAIRE MÉ TAIRE MÉ TAI	DITERRAN Irecteur DE MARSEILL EUSES OUTCOME Hospitals Treatment: DIOGIQUES VZV	IÉE INFEC E Hôpitau Universitair de Morseil ry ation
RRANÉE mples for Phase Gen Rect Urin	ALL OF THE	UN Y KON UN Y KON S. 1327856-9 UN IVERSII SSEUT DIGIER E PUBLIQUE – LE DE MALAD XV DEMANDE D'E MONICYPO MONICYPO	TAIRE MÉ RAOULT - D HÔPITAUX IES INFECTI XAMENS BII X	DITERRAN Irrecteur DE MARSEILL EUSES OUTCOME Ambulato Hospitaliz Treatment: DLOGIQUES VZV	IÉE INFEC E Höpitau Weiverstein de Marseil ry ation IST
mples for Phase Gene Skin Reaction Urin	est of the second secon	UI PA 201 UI PA 201 Sector of the sector o	TAIRE MÉ RAOULT - D HÔPITAUX IES INFECTI XAMENS BIO XAMENS BIO XUILONS TRIPL	DITERRAN Irrecteur DE MARSEILL EUSES OUTCOME Ambulato Hospitalia Treatment: DIOGIQUES VZV	ry ation IST
mples for Phase Gen Rectau Verge Rectau	est of the second secon	UN 74 600 UN 74 600 S. 1327650-0 UNIVERSII Sseur Didler E PUBLIQUE – LE DE MALAD XV DOEMANDE DO MONETPRO	TAIRE ME RAOULT - D HÖPITAUX IES INFECTI XAMENS BIO	DITERRAN Irrecteur DE MARSEILL EUSES OUTCOME Hospitals Treatment: DIOGIQUES VV	Y Ty ation IST
Phanyies for in the phane of th	estantia specific control of the second second of the second of the seco	UI 19 200 UI 19 200 Santa Carlos Construction Sector Didler FUBLIQUE LE DE MALAD DEMANDE D'E MONICIPIO MONICIPIO MONICIPIO HAN SUR ECOU	AIRE MÉ RAQUIT - D HÔPITAUX IES INFECTI XAMENS BI X X IES INFECTI	DITERRAN Irecteur DE MARSEILL FUSES OUTCOME Hopptala Hopptala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotala Ropotal Ropotala Ropotala Ropot	P F F F F F F F F F F F F F
Plane Store	Las a universe and the second	UII 79 200 UII 79 200 S. LISZESSON UNIVERSI SSEUT DIGIEST SSEUT DIGIEST FUDLIQUE LE DE MALAD ELE DE MALAD XV DEMANDE D'C MONETYPO HAN SUR ECOUT	A IRE MÉ RAOULT - D HÖPITAUX IES INFECTI XAMENS BIG X X VILLONS TRIPL	DITERRAN Irecteur De Marseill euses OUTCOME Hospitals Treatment DLOGIQUES VZV	ry ation use
REALES FOR	Alia a Work of the second se	UI 73 200 UI 73 200 S. LI37265-0 UNIVERSI SSEUT DIGIERS I SSEUT DIGIER LE DE MALAD ELE DE MALAD XV DEMANDE D'C MONETIVO HAN SUR ECOU	A IRE MÉ RAQUIT - D HÔPITAUX IES INFECTI XAMENS BII X MILONS TRIPL	DITERRAN DIC MARSEILL EUSES OUTCOME Hospitals Hospitals Treatment DICGIQUES VV V	ry aboo IST
REALES	r RT-PCR MM Professional Control Contr	UNIVERSII Security of the second seco	TAIRE MÉ MARINE MÉ RADULT - LU SES INFECTI X X X X X X X X X X X X X X X X X X X	DITERRAN DITECTEN DE MARSEILL EUSES OUTCOME Anabiato Hospitals Treatment: DIOGIQUES VIV E EMBALLAGE	ry tion uc
mples for Phase Comparison Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase	r RT-PCR MM For the second second second second second for screee second for screee second for HW to	18 Pa 200 18 Pa 200 19 Pa 200 19 Pa 200 UNIVERSII Security Older E PUBLIQUE – E PUBLIQUE – E DE MANDE D'E MONICIPIO ILLAN SUR ECOL DEMANDE D'E MONICIPIO ILLAN SUR ECOL DIALANS UN	ALIRE MINING TARE AND A CONTRACT AND		ry entron BT
RRANEE BRANEE Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Brane Bran	rest for Hill to screece for Hill to be the format of the format oo the format oo	III 9 A 200 III 9 A 200 S. 1327655-0 UNIVERSII Search Didness Search Didness Search Didness Search Didness Search Didness Search Didness Search Didness Sandulin Au C Sandulin Au C Sandulin Au C	ALIRE MI ALIRE MI ALIRE MI ADVIT- D REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REPUTADX REP	DUTTER RAN DITERRAN OUTCOME Anapolato Hospital Norseture DIOGIQUES VEV EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE EEMALLAGE	ry teon UE E

Appendix Figure 1. Standardized medical questionnaire (in English) used for observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France. We used

the questionnaire to obtain demographic information; patient-reported smallpox vaccination status; HIV status; epidemiologic data, including exposure to someone with monkeypox, travel, attendance at large gatherings, and risk factors for sexually transmitted infections; sexual practices; symptoms; virological results at multiple body sites, including analysis of PCR cycle threshold (Ct) values; and co-infection with other sexually transmitted pathogens.

DANÉE		POBLIQUE - HOPII	AUX DE N	ARSEILLE	Hôpitau
W	PÔLE	DE MALADIES INI	FECTIEUSE	s	Universitaira de Marseill
N	IONK	ΕΥΡΟΧ		Etiquet	te patient
EPHONE	PATIENT :		L		
:					
(e : /accination	variole connue	e 🗆 Oui 🗆 Non Si C	UI : Date p	remière dos	e
[] []	□ Séropositivité			restrict do.	10-50
ISH SH	□ Hétéro	sexuel			, ricr
CONSTA	NCES DE CON	TAMINATION			
Voya Rapp Parte Rapp Rapp	ge 3 dernières ort sexuel avec enaire habituel ort sexuel avec	semaines Lieu : nouveau partenaire MPX : multiples partenaire	Da dans les 3 : is dans les 3	te retour : . semaines 8 semaines	
иртома	TOLOGIE	Contac	t Asympto	matique	
e de début	: des symptôme	s://	de début c	les lésions :	
G Fiève	e seudo-grippal				
Adér	opathies				
D Odyr	ophagie				
L Erup	lion □ Papules □ 1	Vésicules 🗆 P	ustules	🗆 Croù	tes 🗆 Rash
C 1	Deussée uniq Prurit	ue	Nombre d	e lésions : N	-
ļ	Atteinte tron	c / paumes et plantes	5	0	」<10] 10 à 50
0	Atteinte des i	inale] > 50
	Atteinte phar	yngée barvogite			
10.21 ha					
тит но	ulevard Jean Mou +33 4 11 www.mediterra F.I.N.E.S.S. DSPITALO- Profe	lin - 13005 Marseille - Fr 73 20 01 nee-infection.com 13078604-9 UNIVERSITAIF sseur Didier RAOI	ance RE MÉDI JLT – Dire	TERRA	IÉE INFE
TUT HO	ulevard Jean Mou +334 1: www.mediterra F.I.N.E.S.S. DSPITALO- Profe ASSISTANCI PÕ	lia - 13005 Marseille - Fr 17 32 00 nee-Infection.com 13078604-9 UNIVERSITAIF sseur Didier RAOI E PUBLIQUE - HÔP LE DE MALADIES I	ance RE MÉD JLT – Dire ITAUX DE NFECTIEU:	ITERRA! ctour MARSEILI SES	IÉE INFE Hõpita Universita de Marse
	ulevard fean Mou +334 21 www.mediterra F.I.N.E.S.S OSPITALO- Profe ASSISTANCI PÕ	IIII - 1303 Marseille - Fr 73 20 01 IIII - 1300 IIII - 1300 IIIII - 1300 IIIII - 1300 IIIII - 1300 IIIIII - 1300 IIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIII	ance RE MÉDI JLT – Dire ITAUX DE NFECTIEU:	TERRAI cteur Marseill Ses Devenir	NÉE INFE Höpita Johverska de Manae
	ulevard fean Mou +33 4 1 www.mediterra F.I.N.E.S.S DSPITALO- Profe ASSISTANCI PÔ HENTS POUR F Davillon pharym	IIII - 1303 Marseile - Fr 73 20 01 IIII eees Infection.com IIII VERSITAIF SSEUE DIdier RAOI E PUBLIQUE - HÖP LE DE MALADIES I PCR 86 86 756	RE MÉDI JLT – Dire ITAUX DE NFECTIEUS	TERRAN cteur MARSEILI SES DEVENIR Rei	NÉE INFE Höpita de Marse cour à domic
	elevard fram Mou elast at ruwermothern ruwermothern schutzs DSPITALO- Profe ASSISTANCI PÓ Verts POUR I Suvillon DGE/V Suvillon DBaryn Suvillon Alastanal Ines	Lin - 1306 Marstille - Fr 17 201 Lin - 1000 Marstille - Fr 13078604-9 LIN VERSITA II Source - Hôp LE DE MALADIES I LE DE MALADIES I LE DE MALADIES I CR gé cutanées	RE MÉDI JLT – Dire TAUX DE NFECTIEU:	TERRAI cteur MARSEILL SES DEVENIR Rei Ho	NÉE INFE E Hôpita Universit do Marso spitalisation Traitement :
	elevar fram Mou a 314 1 umw. a 314 1 provember 2000 FLINESS SSPITALO- Prote ASSISTANCO PO PO NENTS POUR I PO NENTS POUR I PO	III. 1300 Mansile - F. III. 1300 Mansile - F. III. 1307801-9 UNIVERSITAII SSEUF DIGIER RADI E PUBLIQUE - HÔP LE DE MALADIES I CR gé rock cutunées	RE MÉDI JLT - Dire ITAUX DE NFECTIEUS	MARSEILI SES DEVENIR Rei Ho DGIQUES	e Hopita de Manu de Manu tour à domic spitalisation Traitement :
	elevar fram Mou elst at provention of the second function of the second function of the second prote assistance po restriction of the second po restriction of the second po r	III. 1300 Xansile - F III. 1307 Xansile - F III. 1307 Xansile - F UNIVERSITAI III. 1307 Xansile - MÖP LE DE MALADIES I DEMANDE D'EXAM MONEYPOX LANSUR ECOUNLIGI	RE MÉDI JLT - Dire ITAUX DE NFECTIEUS ENS BIOLO	DEVENIR	NÉE INFE Höpita universite de Marse tour à domice spitalisation Trailement :
	elevari fran Mou minimum alloren FilkLESS OSPITALO- Profe ASSISTANCI PÔ IENTS POUR I DUIVIIO DETAVIO VIIIO DETAVIO VIIIO DETAVIO VIIIO DETAVIO	III. 1300 WARSING - Fr III. 1307801-9 UNIVERSITATS IIIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIVERSITATS UNIV	RE MÉD JLT - Dire ITAUX DE NFECTIEU: I I I I I I I I I I I I I I I I I I I	DEVENIR BES DEVENIR BEG DEVENIR BEG DEVENIR BEG BEG BEG BEG BEG BEG BEG BEG BEG BEG	NÉE INFE E Höpita Universite de Marsu sour à domici spitalisation Trailement IST
	vervar fram Mou www.meditorro F.I.N.E.S.S OSPITALO- Profe ASSISTANCI PÖ Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar Vervar	III. 1303/Varsile - F. III. 1303/Varsile - F. III. 1307801-9 UNIVERSITAII SSEUP DIAIER AND E PUBLIQUE - HÔP LE DE MALADIES I PCR gé rok cutunées DEMANDE D'EXAM MONGYPOX III. 1001/VILID	RE MÉDI JLT - Dire ITAUX DE NFECTIEU: ENS BIOLO VZV VS TRIPLE EN	DEVENIR BES DEVENIR BEG DEVENIR BEG BEG BEG BEG BEG BEG BEG BEG BEG BEG	Cour à domic policies de Marai cour à domic spitalisation Traitement
	vervar fram Mou www.meiterror F.I.N.E.S.S OSPITALO- Profe ASSISTANCI PÔ HENTS POUR I New John State New John St	III. 1300 Xansile. F Res ¹ /JCCID. CONTRACTOR III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III. III	RE MÉDI JLT - Dire ITAUX DE NFECTIEUS I I I I I I I I I I I I I I I I I I I	DEVENIR Bes Devenir Bes Devenir Bes Bes Bes Bes Bes Bes Bes Bes Bes Bes	NÉE INFE Höpita Gewerste de Mans tour à domic spitalisation Traitement IST
TUT HC	verver fram Mou www.mediterre F.I.N.E.S.S OSPITALO- Prote ASSISTANC PO Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver Verver V	III. 1300 VARISIE - F. III. 1300 VARISIE - F. III. 1307801-9 UNIVERSITAII SISUE OIGEN ADD E PUBLIQUE - HÔP E PUBLIQUE - NÔP E PUBLI	RE MÉDI JIT – Dire ITTAUX DE NFECTIEUS I I STRIPLE ER RCAS HONI	ITERRAI Crear MARSEILI MARSEILI SES DEVENIR Reference NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQUES NGIQU	Cour à domini cour à domini pitalisation Traitement
TUT HC	vervar fan Mou www.mediterer FJ.N.E.S.S DSPITALO- Profe ASSISTANCI PÔ IENTS POUR I Duvillen pharyn Juvillen pharyn Juvillen pharyn Juvillen pharyn Juvillen pharyn Juvillen pharyn Juvillen pharyn Juvillen gharyn Juvillen gh	III. 1300 VARISIIE - FA III. 1307 VARISIE - FA III. 1307 VARISIE - FA III. 1307 VARISIE - FA SSEUT DI JER E PUBLIQUE - HÔP LE DE MALADIES I CR B ⁶ CR B ⁶ CR DEMANDE D'EXAM MONNETYON III. MANUE COUVILLO III. 1000 VARISIE SANGUIN AU CAS PA	RE MÉDIUT - Dire IITAUX - Dire IITAUX DE ENS BIOLO V2V2 V2V2 V2V2 V2V2 V2V2 V2V2 V2V2 V	ITERRAJ MARSEILI SES DEVENIR BRIDUES MIRALAGE	our à domin spitalisation traitement 157
	Lever and Mage www.mediterer F.I.N.E.S.S SSPITALO- Profe ASSISTANCI PO LEWIS POUR PO LEWIS POUR PO LEWIS POUR PO LEWIS POUR PO PO LEWIS POUR PO LEWIS POUR POUR POUR POUR POUR POUR POUR POUR	III. 1300 YAAASIB - FA See - Infection - FA III. III. III. III. III. III. III. III	ARCE MÉDIJIT – DIRG NITAUX DE LE ENS BIOLLO VZV VS TRIPLE ER	ITERRAI CCCUT SES SES DEVENIR Rei Ho MBALLAGE	LEE INFE Hopital de Margar de Margar
TUT HC	verw.meditors F.I.N.E.S.S SSPITALO- Profe ASSISTANCI PO NENTS POUR I NEWTS POUR I NEWTS POUR I NEWTS POUR I NEWTS POUR I NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS NEWTS	III. 1300 VARISIE - F. SECONTRESIDENTIALIS UNIVERSITATI UNIVERSITATI UNIVERSITATI SECONTRESIDENTIALIS UNIVERSITATI DEMANDE D'EXAM DEMANDE D'EXAM DEMANDE D'EXAM DEMANDE D'EXAM DEMANDE D'EXAM ISANGUN AU CAS PA	REMÉDI LIT - Dire ITAUX DE ENS BIOLO VEV VEV REAS NON 3	ITERRAI Cteur MARSEILI SES DEVENIR Rete Ho Ho NGIQUES MARLAGE	e Höpitaki de Marsu oour à domini istraileation istraileation
TUT HC	verver and book of the second	III. 1300 VARISIE - F. Ser-Infection.com 13078604-9 UNIVERSITATI SERVE DIdier RAOI 13078604-9 UNIVERSITATI SERVE DIdier RAOI PCR 8 ⁶ CCR 8 ⁶ CCR 8 ⁶ CUBANDE D'EXAM MONRYPOX INAN SUR ECOUVILLO	RE MÉDI JIT - DIFE ITAUX DE NFECTIEUX I UX VZV VZV VZV VZV VZV	ITERRAI CCOURT MARSEILI SSS DEVENIR Relate Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual Manual M	our à domin de Marsu de Marsu Jerreitation 197
	Verw.meditors F.I.N.E.S.S SSPITALO- Prote ASSISTANCI PO Verview Construction PO Verview Construction P	III. 1300 VARISHE - Fr Second Control	RE MÉDI JIT - Dire ITAUX DE NFECTIEUS I STOLE STOLE RCAS NON 1 RCAS NON 1	ITERRAI CCOUR MARSEILI SES DEVENIR BRIQUES MBRILAGE MBRILAGE MBRILAGE	our à domini de Morse our à domini president 57 T y compris
RELEVENCE	Vervar Beider an Mou vervar.meiderer PLAESS DSPITALO- Profe ASSISTANCI PÖ HENTS POUR I PÖ HENTS POUR I HENTS POUR	III. 1300 VARSIE - F. Serificeion.com 1307801-9 UNIVERSITAII SSEUP DIAIER RADI E PUBLIQUE - HÔP LE DE MALADIES I CCR gê TYRE CUTURÔES DEMANDE D'EXAM MONNETPOR III. III. III. SANGUIN AU CAS PA decin au patient de fa nné son accord clair i	RE MÉDI LLT - Dire ITAUX DE NECTION ENS BIOLOGI VAV VAV VAV VAV VAV VAV VAV VAV VAV VA	ITERRAI Ctear MARSEILI SES DEVENIR BRALLAGE BRALLAGE SYSTEMATIC STATES AND	our à domin de Marsu uer traitement traitement traitement

Appendix Figure 2. Standardized medical questionnaire (in French) used for observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France. We used the questionnaire to obtain demographic information; patient-reported smallpox vaccination status; HIV

status; epidemiologic data, including exposure to someone with monkeypox, travel, attendance at large gatherings, and risk factors for sexually transmitted infections; sexual practices; symptoms; virological results at multiple body sites, including analysis of PCR cycle threshold (Ct) values; and co-infection with other sexually transmitted pathogens.



Rectal samples

Appendix Figure 3. Comparison of monkeypox virus loads in rectal samples from symptomatic and asymptomatic patients in Marseille in an observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France, 2022. We tested rectal swabs from symptomatic (n = 62) and asymptomatic (n = 6) patients for monkeypox virus by using quantitative PCR and calculated the mean Ct for each group. We found no difference in viral loads between the groups. Ct, cycle threshold; ns, not significant.

Samples



Appendix Figure 4. Comparison of monkeypox virus loads in clinical samples from patients with HIV and those without HIV infections in Marseille in an observational cohort study of evolving epidemiologic, clinical, and virological features of monkeypox in southern France, 2022. We tested clinical samples for monkeypox virus by using quantitative PCR. We collected samples from skin (n = 69), genital (n = 67), rectal (n = 68), and pharyngeal (n = 50) swabs and calculated the mean Ct for each sample type. We found no differences in viral loads between the groups. Ct, cycle threshold; ns, not significant.